Prosecution Insights
Last updated: July 17, 2026

Cepeda Patent Law, Llc.

8 pending office actions • 3 clients • 8 examiners • 6 art units • 0 of 8 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days

Quality Metrics (n=32 apps, methodology: how we score firms)

27.3%
Allowance Rate
n=32
-0.17σ
Allowance Rate (norm)
n=32
OAs to Allowance
n=3 (min 20)
OAs to Allow (norm)
n=3 (min 20)
Time to Allowance
n=3 (min 20)
+80.0pp
Interview Lift
n=32
18.2%
RCE Rate
n=32
0.0%
Appeal Rate
n=32

Rejection Performance (% of received rejections ultimately overcome)

§101 Overcome
n=1 (min 20)
§102 Overcome
n=1 (min 20)
§103 Overcome
n=8 (min 20)
§112 Overcome
n=4 (min 20)

Specialization & Scale

C07K, A61K, A61P
Top CPC Subclasses
72%
Top-3 CPC Share
n=32
0
Practitioners
n=32
Apps / Practitioner
n=32 (min 20)

Portfolio Summary

8
Total Pending OAs
7
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
2
Due this month
0
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (1)Due ≤ 30 days (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
5
Medium (62%)
3
Easy (38%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only4 (50%)
§112 only1 (12%)
Double-patenting only2 (25%)
Double-patenting + other1 (12%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
75% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
2
Business / Other
25% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
LANDSMAN, ROBERT S 1 81.4% +13.1%
VAN DRUFF, SYDNEY 1 56.4% +29.5%
TSAY, MARSHA M 1 45.7% +52.4%
TAYLOR, LIA ELAN 1 64.1% +28.6%
CORNET, JEAN P 1 42.0% +47.6%
MCCOLLUM, ANDREA K 1 60.9% +32.1%
ISMAIL, REHANA 1 78.3% +31.6%
MOORE, SUSANNA 1 68.0% +31.6%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18681162 Method To Purify An Antibody Composition Using Cation Exchange Chromatography LANDSMAN, ROBERT S

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17766823 STABLE FORMULATION OF INTEGRIN ANTIBODY MCCOLLUM, ANDREA K 18d overdue
18275255 CELL CULTURE METHODS TSAY, MARSHA M 8d
17058390 PRODRUGS OF FULVESTRANT MOORE, SUSANNA 27d
18681162 Method To Purify An Antibody Composition Using Cation Exchange Chromatography LANDSMAN, ROBERT S
18291909 Method To Control High Molecular Weight Aggregates In An Antibody Composition VAN DRUFF, SYDNEY
18273142 FREEZE DRIED ANTIBODY FORMULATIONS AND METHODS THEREOF TAYLOR, LIA ELAN
17779015 PRODRUGS OF FULVESTRANT CORNET, JEAN P
17623556 CHEMICAL INHIBITORS OF ID PROTEINS FOR THE TREATMENT OF CANCER AND OTHER DISEASES ISMAIL, REHANA

Client Portfolio (3 clients)

Client (Assignee)Pending OAs
Dr. Reddy's 5
KASHIV BIOSCIENCES, LLC 2
Heidelberg University 1

Top Art Units

Art UnitApps
16561
16411
16281
16741
16251
16241

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18681162 Method To Purify An Antibody Composition Using Cation Exchange Chromatography DR. REDDY'S LABORATORIES LIMITED LANDSMAN, ROBERT S DP Non-Final OA Pending Feb 05, 2024
18291909 Method To Control High Molecular Weight Aggregates In An Antibody Composition DR. REDDY'S LABORATORIES LIMITED VAN DRUFF, SYDNEY §103 Non-Final OA Pending Jan 24, 2024
18275255 CELL CULTURE METHODS DR. REDDY'S LABORATORIES LIMITED TSAY, MARSHA M 1656 §103 Non-Final OA 8d Pending Aug 01, 2023
18273142 FREEZE DRIED ANTIBODY FORMULATIONS AND METHODS THEREOF DR. REDDY'S LABORATORIES LIMITED TAYLOR, LIA ELAN 1641 DP Non-Final OA Pending Jul 19, 2023
17779015 PRODRUGS OF FULVESTRANT Kashiv Biosciences, LLC CORNET, JEAN P 1628 DPOther Non-Final OA Pending May 23, 2022
17766823 STABLE FORMULATION OF INTEGRIN ANTIBODY DR. REDDY'S LABORATORIES LIMITED MCCOLLUM, ANDREA K 1674 §112 Final Rejection 18d overdue Pending Apr 06, 2022
17623556 CHEMICAL INHIBITORS OF ID PROTEINS FOR THE TREATMENT OF CANCER AND OTHER DISEASES UNIVERSITAT HEIDELBERG ISMAIL, REHANA 1625 §103 Non-Final OA Pending Dec 28, 2021
17058390 PRODRUGS OF FULVESTRANT Kashiv Biosciences, LLC MOORE, SUSANNA 1624 §103 Non-Final OA 27d Pending Nov 24, 2020

Managing Cepeda Patent Law, Llc.'s Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month